• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Patient Preference Not a Good Predictor of Treatment Response

Patient Preference Not a Good Predictor of Treatment Response

June 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Subject:
Patient Preference

Short Description:
Patient Preference Not a Good Predictor of Treatment Response

Background:

Do patients with major depressive disorder (MDD) respond better when psychiatrists offer the type of treatment—medication or psychotherapy—that the patient prefers? And do patients’ beliefs about what causes their depression influence treatment outcomes? In a new study, researchers concluded that, despite their expectations, neither factor is a good predictor of treatment response.

Researchers looked at 80 patients who participated in a 12-week randomized, double-blind clinical trial of MDD. They assessed the patients’ treatment preference, the strength of that preference, and their beliefs about the causes of their depression before the subjects entered into the clinical trial. The majority (45 patients) expressed a preference for one of the two types of treatment, but all were randomly assigned to receive either 16 sessions of cognitive behavioral therapy (CBT) or a daily dose of the antidepressant escitalopram (Lexapro).

The researchers measured response by three commonly used rating scales. Contrary to the researchers’ hypothesis, neither patients’ preferences, nor the strength of that preference, influenced remission rates at the end of the 16-week trial. Furthermore, patients who did not receive their preferred treatment were no more likely to drop out of the trial than others.

The researchers also expected to find that remission rates would be greater when patients believed the cause of their depression matched the underlying mechanism of their assigned treatment. For instance, patients who believe that depression is a biochemical disorder might respond better to an antidepressant medication. However, there was no correlation between individual beliefs about the origin of their depression and remission based on treatment type.

One limitation of the study was a moderate sample size. Another was the fact that researchers did not ask about negative attitudes towards treatment, only “preferences.” It’s quite possible that critical attitudes toward medication-based approaches, or particularly bad experiences with therapy or medications in the past, might result in poorer outcomes. However, even if such strong beliefs existed, most (81%) patients remained in the trial for the full 16 weeks (Dunlop B et al, J Psychiat Res 2012;46(3):375–381).

TCPR's Take:
Past studies have produced mixed results when it comes to the question of whether patients do better when offered the treatment option they prefer (see Swift JK et al, J Clin Psychol2009;65(4):368–381). One study (Mergl R et al, Psychother Psychosom 2011;80(1):39–47) covered in the February 2011 issue of TCPR, compared SSRI versus group therapy for patients with minor depression, and found that no one who expressed a preference for sertraline (Zoloft) remitted with psychotherapy. Several other studies have found the opposite. It’s possible that patient preference is actually a surrogate marker for some other predictor, like a personality factor (eg, inhibition in social settings) or past experience with either meds or therapy. A limitation in all randomized studies comparing highly different treatment methods is that patients with the strongest preferences about treatment are typically not included or simply choose not to participate.
General Psychiatry
KEYWORDS depressive_disorder research_updates
Ccpr octnovdec2020 qa1 headshot spielmans 150x150
Glen Spielmans, PhD

Two New Meta-Analyses Compare Antidepressants

More from this author
www.thecarlatreport.com
Issue Date: June 1, 2012
SUBSCRIBE NOW
Table Of Contents
Seven Clinical Pearls for Suicide Risk Assessment
Managing the Risk of Prescription Drug Abuse
How to Reduce Risk for You and Your Patients
Patient Preference Not a Good Predictor of Treatment Response
Text Messaging Effective for Appointment Reminders
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.